Moderna, Inc.
MRNA
Kedudukan dalam Saham
#239
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Harga Saham
$241.53
Modal Pasaran
$96.43B
Perubahan (1 hari)
6.45%
Perubahan (1 tahun)
786.67%
Negara
US
Perdagangan Moderna, Inc. (MRNA)
Kategori
Healthcare
Nisbah P/E bagi Moderna, Inc. (MRNA)
Nisbah P/E pada October 2026 TTM: -28.36
Menurut laporan kewangan dan harga saham terkini Moderna, Inc., nisbah P/E semasa (TTM) ialah -28.36. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -8.06.
Sejarah nisbah P/E bagi Moderna, Inc. dari 2016 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -28.36 | 533.00% |
| 2024 | -4.48 | -44.36% |
| 2023 | -8.06 | -195.22% |
| 2022 | 8.46 | 0.89% |
| 2021 | 8.39 | -115.73% |
| 2020 | -53.33 | 323.62% |
| 2019 | -12.59 | -3.54% |
| 2018 | -13.05 | -52.25% |
| 2017 | -27.33 | 395.62% |
| 2016 | -5.51 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -201.49% |
US
|
|
| -24.57 | -13.37% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -206.95% |
NL
|
|
| 17.49 | -161.67% |
BE
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.